[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, avelumab has been shown to be effective for the treatment of urothelial carcinoma. The JAVELIN Bladder 100 trial, a phase 3 randomized trial, demonstrated that avelumab maintenance therapy significantly prolonged overall survival compared to best supportive care alone in patients with advanced urothelial carcinoma. The trial included 700 patients and showed that avelumab treatment resulted in a median overall survival of 21.4 months compared to 14.3 months in the control group. Additionally, avelumab has been approved by the FDA for the treatment of metastatic urothelial carcinoma. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]